Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women

Context:Elagolix is a nonpeptide, oral gonadotropin-releasing hormone (GnRH) antagonist being developed for sex-hormone–dependent diseases in women.Objective:We evaluated the pharmacokinetics and pharmacodynamics of elagolix.Design, Setting, and Participants:This study was a randomized, double-blind...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2017-05, Vol.102 (5), p.1683-1691
Main Authors: Ng, Juki, Chwalisz, Kristof, Carter, David C., Klein, Cheri E.
Format: Article
Language:English
Subjects:
17β-Estradiol
Adult
Adverse events
Dosage
Dose-Response Relationship, Drug
Double-Blind Method
Estradiol - metabolism
Female
Follicle Stimulating Hormone - metabolism
Follicle-stimulating hormone
Gonadotropin-releasing hormone
Gonadotropin-Releasing Hormone - antagonists & inhibitors
Gonadotropins
Headache
Healthy Volunteers
Hormone Antagonists - pharmacology
Hormone replacement therapy
Hormones
Humans
Hydrocarbons, Fluorinated - pharmacology
Luteinizing hormone
Luteinizing Hormone - drug effects
Luteinizing Hormone - metabolism
Middle Aged
Ovaries
Pharmacodynamics
Pharmacokinetics
Pituitary (anterior)
Placebos
Premenopause
Progesterone
Progesterone - metabolism
Pyrimidines - pharmacology
Sex hormones
Soy products
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!